Member Info for NFTs

Since the patients have already undergone multiple prior therapies, including likely exposure to doxorubicin or similar drugs, their tumors may have developed resistance to doxorubicin.

What makes this study notable is that despite this potential resistance, AVA6000 delivers much higher concentrations of free doxorubicin directly into the tumor, which may help overcome some resistance mechanisms. The targeted delivery could increase the drug’s effectiveness where conventional doxorubicin failed or was less effective due to lower tumor exposure.

So, even in patients with potentially resistant tumors, the new formulation shows promising activity by concentrating the drug in the tumor microenvironment while reducing side effects. This suggests the approach might partially bypass typical resistance seen with standard doxorubicin treatment.

So a run down on the below nothing anyone probably doesn’t already know but if it’s better than standard Doc it becomes the new Dox.!!!

Basic Understanding

• 63 patients with advanced cancer, many of whom had tried other treatments, received different doses of AVA6000.

• The drug was generally well tolerated, with the most common serious side effects being blood-related issues like low white blood cells (neutropenia, leukopenia, lymphopenia).

• Serious heart problems, often a concern with doxorubicin, were not observed even at high doses.

• Compared to traditional doxorubicin, AVA6000 resulted in much lower drug levels in the blood but much higher levels inside the tumors (about 100 times higher).

• This selective delivery helps target the tumor while reducing damage to healthy tissues, including the heart.

• Some patients with specific tumor types (FAPhigh tumors, like salivary gland cancer and soft tissue sarcoma) showed tumor shrinkage or minor improvement, indicating the drug is active against these cancers.

How Good Is It?

• The safety profile so far is encouraging, especially the reduced heart toxicity risk, which is a major limitation of regular doxorubicin.

• The drug achieves much higher concentrations of the chemotherapy agent in the tumor than in the blood, which is ideal for effectiveness and reducing side effects.

• Early signs of tumor response mean it has potential as a treatment, especially for tumors with high FAP expression.

• Being a Phase 1 study, these results primarily show safety and dosing, but the effectiveness signals are promising for further testing.

In short, AVA6000 appears to deliver chemotherapy more directly to tumors with fewer side effects, making it a potentially better and safer option compared to traditional doxorubicin.

In basic terms, this means the amount of free doxorubicin (dox) in the tumor was about 100 times higher than the amount in the blood plasma

Thanks Stonks on X

https://cslide.ctimeetingtech.com/esmo2025/attendee/confcal_2/presentation/list?q=Ava6000

Background

FAP-Dox (AVA6000) is a peptide drug conjugate (PDC), comprising doxorubicin (dox) bound to a peptide by a linker that is specifically cleaved by FAP, which is overexpressed in the TME of many solid tumors.

Methods

The safety, PK and preliminary efficacy of AVA6000 was studied in a first-in-human, multicenter phase I trial. AVA6000 was administered i.v. using a 3+3 design in pts with locally advanced or metastatic solid tumors categorized as high to mid range FAP (FAPhigh and FAPmid). AUC based dosing was implemented to calculate maximum number of AVA6000 cycles.

Results

Final Phase 1 data with 63 pts (median age 60 yr, range 30-79), median 2 prior therapy lines (range, 0-7) received escalating AVA6000 doses from 80 to 385 mg/m2 i.v. q3w; the starting dose was 160 mg/m2 in the q2w arm. The safety profile was favorable with frequent grade 3-4 hematologic toxicities of neutropenia (19%), leukopenia (9.5%), and lymphopenia (6.3%). Non-hematologic grade 3/4 toxicity in >2pts were limited to fatigue (n=2, 3.2%). Three pts with DLTs were observed: grade 2 cardiac failure (120 mg/m2), grade 3 febrile neutropenia (385/200 mg/m2) and grade 4 neutropenia/ thrombocytopenia (200 mg/m2) in 1 pt. No severe cardiac events were observed despite dosing up to the equivalent dox exposure associated with a lifetime max dose of 550 mg/m2. Compared to conventional dose dox, PK showed reduced systemic exposure (AUC, 5-77% reduction v. conventional dox) and peak concentration (Cmax,78-93% reduction). Concentrations of free dox in tumor were ∼2 log higher than plasma. PK modelling showed that conventional dox and released dox have different first pass effects, limiting the exposure of normal tissues to low released dox including the heart. Four PR and 5 minor responses were observed in pts with FAPhigh tumor types including salivary gland cancer and soft tissue sarcoma.

Conclusions

AVA6000 is active in FAPhigh tumors and well tolerated, delivering high concentration of free dox to the TME relative to plasma. Multiple responses were observed in patients indicating activity of the PDC. The pre|CISION PDC concentrates payload in the TME while sparing normal tissues from exposure.

Given Jadestone Energy’s contingent resources of approximately 171.3 billion standard cubic feet (Bscf) at Nam Du and U Minh, and using an average price around $12-$14 per MMBtu, the gross market value of the recoverable gas could be in the range of:

171.3 \text{ Bscf} \times 1,000 \text{ MMBtu/Bscf} \times 12 \text{ USD/MMBtu} = 2.0556 \text{ billion USD}

This represents a very approximate gross value before costs, taxes, and other deductions. The actual net value to Jadestone would be lower after accounting for production costs, royalties, PSC terms, and capital expenditures.

In summary, the gas reserves Jadestone holds in Vietnam could be worth around $2 billion in gross market value at current gas prices.

Https://www.reuters.com/sustainability/boards-policy-regulation/ftse-russell-upgrades-vietnam-emerging-markets-status-2025-10-07/

It’s at an interesting point. The traders will be watching the TA but it’s already broken into higher bullish wave 3.

The problem the TA lot have it’s got ESMO and interesting news momentum so it most likely continue to resist the TA line and keep pushing.

Any drop would be a quick dip either or it’s good but it may well not play and keep pushing.

When a stock is hot it can really break and AVACTA is fundamentally so undervalued for what it sits on anything can happen.

Just great to see it waking up and doing what we all knew it would.

Only a fool would try playing it down and there have been plenty of them.

We heard that feedback, and we absolutely take that on. We’re also going to commit to organizing live events. Shareholders have the opportunity to meet the management team, the scientists at Avacta, and to ask questions of us. We had a very good interaction at the AGM, and we will continue to build on that.

Also, let me also mention that we have our regular R&D spotlight series videos that we put those on both the X platform and LinkedIn, and those will start to come through the investor meet as well. So you don’t have to go to social media. That’s another that we’ve heard. This is to educate on the pipeline.

And we’re very grateful for our shareholders who have come along with us. This has been a dream of mine is to really impact cancer, and Avacta is doing it. So proud of all the scientists here, grateful to the sites, the clinical trial sites and very grateful, at the end of the day, to the patients who have signed up for our trials. I think we’ve got a very bright future in front of us.

Operator:

Chris, thank you very much indeed. Chris, Brian, thank you very much indeed for updating investors. If I could please ask investors not to close the session. We’ll now automatically redirect you to the opportunity to provide your feedback in order that the company can better understand your views and expectations. This may take a couple of moments to complete, but I’m sure it’ll be greatly valued by the company.

On behalf of the management team of Avacta Group plc, we’d like to thank you for attending today’s presentation, and wish you all a good rest.

Christina Coughlin, CEO:

Sure. It’s completely understandable. We know that this is a recurring theme for our shareholders, and we appreciate the comments that we get here. I’ve already shared a lot as to our expectations here. But let me wax poetic on this a bit.

We are in multiple conversations across multiple assets. The data in Phase 1b does continue to mature, which is really strengthening Avacta’s position here. On timing, I can’t give definitive answers, that wouldn’t be appropriate. But what I can tell you though is that the team has a clear plan and we are executing on that plan. We have a number of touch points with a number of potential partners coming up.

Our objective is really to exploit the potential of this technology for the benefit of patients and shareholders. And so whilst it may not be reflected in our share price today, these improving data sets, both clinical, but also on the preclinical side of things that we are seeing, these really strengthen the intrinsic value of our technology. We’re looking to leverage this value for shareholders, and we will continue to update as we can on this particular topic.

Operator:

Great. Thank you. I guess a question really relevant to all those over 1,000 people that registered for today’s call. Around the share price really, why does the share price still not reflect the value in today’s pipeline?

Brian Hahn, CFO:

Biotech really follows a normal path. The only constant is good technology ends up with partnerships or buyouts. Avacta has a clear strategy, which it’s executing, and we have shown in the clinic that our tech does what we designed it to do, concentrate the drug in the tumor while sparing healthy tissue from toxicity.

Operator:

That’s great. Thanks, Brian. Okay. Commercial strategy, I guess you have touched a bit on this throughout your presentation, but I wondered if you could just share a little bit more on your commercial strategy with those on the call.

Christina Coughlin, CEO:

Our approach is to really provide, what we think are informative deep dives into our progress, the clinical and the preclinical programs, and we try to do that at regular scheduled points through the calendar year when the need arises.

We have investor engagement events such as this one. We have also listened to feedback from investors. So specifically at the AGM and we are responding to that. We will schedule investor meet presentations around every data release. And so I can commit to you that we will have an investor meet around the ESMO Congress. We will also have an investor meet later in October around that pipeline update. And then as we go deeper into this year, we will also host an investor meet around the data that will be released from the expansion cohorts.

We heard that feedback, and we absolutely take that on. We’re also going to commit to organizing live events. Shareholders have the opportunity to meet the management team, the scientists at A

Operator:

Good afternoon, ladies and gentlemen, and welcome to the Avacta Group plc Interim Results Investor Presentation. Due to the significant attendance on today’s call, the company will not be able to answer every question during the meeting, but will review all questions submitted today and publish responses as appropriate. I’ll now hand over to management.

Christina Coughlin, CEO:

Thank you, and good afternoon. We are pleased to present the interim results for the six months ended June 30, 2025, marking a continued phase of transformation and strong progress for Avacta. Our focus remains sharply on advancing the clinical pipeline centered around the proprietary pre|CISION® peptide drug conjugate platform, which we believe positions us uniquely in targeted oncology therapeutics.

The enrollment and initial data from our Phase 1b expansion cohorts in the faridoxorubicin program (FAP-Dox, AVA6000) have been highly encouraging, reinforcing our confidence in the platform’s value and utility. We also remain on track to dose the first patient in the FAP-EXd (AVA6103) program in Q1 2026, which expands our pipeline into new modalities.

During the recent American Association of Cancer Research Annual Meeting (AACR), we presented translational data supporting these efforts and will soon present the finalized Phase 1a dose escalation data for faridoxorubicin at ESMO 2025 in October, including extended cardiac safety and updated efficacy data.

From a financial perspective, we have raised £6.5 million gross to fund two bond payments in July and October and successfully renegotiated terms for the Heights Convertible Bond to preserve financial flexibility. As of mid-year, our cash balance stood at £12.65 million, which supports our ongoing operational needs.

Looking ahead, we anticipate multiple pipeline data readouts in the last quarter of 2025, including the first expansion cohort in salivary gland cancer. We expect these data and progress on partnering efforts to generate increasing industry interest.

We remain confident in the transformative potential of our unique technology and are dedicated to aggressively advancing these assets toward commercial value for shareholders.

Thank you for your ongoing support. We look forward to updating you as we advance through the year.

Brian Hahn, CFO:

Thank you, Christina. I’ll now provide a brief overview of the financial performance and liquidity position post period end…

Operator:

Thanks, Chris. I guess we’ve been discussing imminent license deals and partnerships now for several months, but nothing has materialized. Can you comment on where you are with this?

Christina Coughlin, CEO:

Sure. It’s completely understandable. We know that this is a recurring theme for our shareholders, and we appreciate the comments that we get here. I’ve already shared a lot as to our expectations here. But let me wax poetic on this a bit.

We are in multiple conversations across multipl

Last golden cross was Oct 2023.

One thing we know is RH seen the plan got onboard with it to deliver it.

What that plan is is anybody’s guess as there are so many options on how they deliver the platform.

But with so many big potential directions with huge potential those options will be very significant for us shareholders and the figures are many multiples higher than any averages people hold. Even if you joined here 15 years ago!

Next few months very exciting and the SP will rocket.

That’s a huge RNS

Shows the platform is working to the money world

Shows they have no issues getting backing

Shows they have confidence in deals

Shows they have next stages sorted

Shows the Shareprice is going to smash new highs

Big Step Bold and exciting

Into 60’s next without any difficulty. Ready for the next setup towards 80’s and £1.

Why it’s still priced so stupidly low is just a failure of UK markets.

The investment case here is probably the best you will see in a decade.

Will become a mark imo of AIM history and UK plc over this next 18 months.

No going back now.

Thing is the GSA short was there as a manipulator to aid whoever it was that found it useful.

It’s certainly been a significant pull on the share along with the HCI loan.

All history now and with the city money now being drawn in with the professional support of Zeus and Richard Hughes and his team, this is most definitely the start of the accent.

The platform is a monster and far more proven than the market has credited it for.

COS as we know is far higher than the broker notes have stated as they have models based on using new drugs and no model for adjustment.

Data rich is AVACTA and major readouts coming later this year.

Deal with Merk perhaps for one of their own drugs to be used with Precision.

IMO that partnership is a major tell tail of further partner / TO.

I sincerely could not imagine Merk wanting to see competitors hit them with a far improved version of their own drugs.

The only price though will be the final price and with that we could see some major players stepping in with some huge offers.

Not yet but we are not far from that point. 12 to 18 months and this may no longer exist. If we get as far as first human data on AVA6103 next year I would be disappointed if we see less than 10bil on first approach. £20

Thing is the GSA short was there as a manipulator to aid whoever it was that found it useful.

It’s certainly been a significant pull on the share along with the HCI loan.

All history now and with the city money now being drawn in with the professional support of Zeus and Richard Hughes and his team, this is most definitely the start of the accent.

The platform is a monster and far more proven than the market has credited it for.

COS as we know is far higher than the broker notes have stated as they have models based on using new drugs and no model for adjustment.

Data rich is AVACTA and major readouts coming later this year.

Deal with Merk perhaps for one of their own drugs to be used with Precision.

IMO that partnership is a major tell tail of further partner / TO.

I sincerely could not imagine Merk wanting to see competitors hit them with a far improved version of their own drugs.

The only price though will be the final price and with that we could see some major players stepping in with some huge offers.

Not yet but we are not far from that point. 12 to 18 months and this may no longer exist. If we get as far as first human data on AVA6103 next year I would be disappointed if we see less than 10bil on first approach. £20

Guess we won’t be seeing any spam childish articles in share profits trying to spam the internet with false info!!!! Hey Thorg

Feeding pizza face to promote FUD.

The context that Alastair used the share price at the time was regarding raising funds would be easier it wasn’t to do with the intrinsic value at the time because in that same video discussion he stated he valued AVACTA at that moment in time to be 2 billion!!

All about using words to suit your agenda pizza boy in North Wales hiding.

Merck’s top-selling drug, Keytruda, faces key U.S. patent expirations in 2028, threatening nearly half of Merck’s revenue and prompting the company to seek new patent strategies and business development deals.

• Merck has aggressively expanded its Keytruda patent portfolio, including new formulations and delivery methods, to delay biosimilar competition and extend exclusivity, with some patents potentially lasting into the 2030s.

• Avacta’s recent patent filings focus on its proprietary precision platform and next-generation peptide drug conjugates, making it an appealing partner for companies like Merck that need innovative solutions to major patent cliffs.

• While there is no direct evidence that Avacta’s latest patents were filed specifically for Merck’s use, their timing and focus are likely strategic, enhancing Avacta’s value and attractiveness to large pharma partners facing patent expiries.

• If Merck were to leverage Avacta’s technology to secure new intellectual property around Keytruda or other assets, it could be a significant deal for both companies, especially if Avacta’s clinical data strengthens its position.

He works on data analysis when looking at potential investments.

Heavy DATA driven business man.

I expect he will have seen a lot more data ongoing than anyone here.

That data no surprise here has made him want to join the BOD.

I guess when seeing the obliterated cancer using AVA6103 and seeing TNBC etc possibly with AVA6k and the previous 4 years of data!!!

He has gone all in as to the fact of joining the BOD.

Now that’s exactly the kind of support AVACTA needs right now.

Watch these city financiers drive the money side here at AVACTA. It’s definitely late as we could done with this 1 year ago but nonetheless it’s happening!!!!